CLINICAL_TRIALS
trial_result
· 2020-06-09
Clinical Trial Update: An Efficacy and Safety Study of Infliximab Dose Escalation in Pediatric Participants With Inflammatory Bowel Disease [Phase 4]
Summary
A Phase 4 study assessing infliximab dose escalation in pediatric inflammatory bowel disease was terminated; results have been posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Janssen Scientific Affairs, LLC | Conditions: Inflammatory Bowel Diseases | Phase 4 | Status: TERMINATED | Results posted: 2020-06-09